Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Receivables (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Receivables readings, the most recent being $425000.0 for Q4 2025.

  • On a quarterly basis, Receivables fell 64.58% to $425000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $425000.0, a 64.58% decrease, with the full-year FY2025 number at $425000.0, down 64.58% from a year prior.
  • Receivables hit $425000.0 in Q4 2025 for Arcadia Biosciences, down from $831000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $3.9 million in Q2 2022 to a low of $304000.0 in Q3 2023.
  • Median Receivables over the past 5 years was $1.1 million (2021), compared with a mean of $1.3 million.
  • Biggest five-year swings in Receivables: soared 289.54% in 2021 and later tumbled 88.85% in 2023.
  • Arcadia Biosciences' Receivables stood at $1.4 million in 2021, then decreased by 12.41% to $1.2 million in 2022, then plummeted by 57.83% to $506000.0 in 2023, then soared by 137.15% to $1.2 million in 2024, then crashed by 64.58% to $425000.0 in 2025.
  • The last three reported values for Receivables were $425000.0 (Q4 2025), $831000.0 (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.